Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 1Osteosarcoma 1Neoplasms 1Inflammation 1Cognitive Dysfunction 1Chemotherapy-Related Cognitive Impairment 1Autoimmune Diseases 1

Interventions

telitacicept 3fludarabine 3Prednisone 3Cyclophosphamide 3Specimen Handling 2Nivolumab 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1Vitamin D 1Valsartan 1Pyridostigmine Bromide 1Population Groups 1Platinum Compounds 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Music Therapy 1Melphalan 1Ipilimumab 1Infliximab 1Immunoglobulins, Intravenous 1Hydroxychloroquine 1Fish Oils 1Fatty Acids, Omega-3 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Autoimmune Diseases × Ashwagandha × Clear all
NCT00817752 2010-03-18

Ashwagandha: Effects on Stress, Inflammation and Immune Cell Activation

National University of Natural Medicine

Phase 1 Completed
25 enrolled

Autoimmune Diseases, Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡